Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Inferior Vena Cava Diameter and Postpartum Hemorrhage

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03732079
Recruitment Status : Unknown
Verified November 2018 by HaEmek Medical Center, Israel.
Recruitment status was:  Not yet recruiting
First Posted : November 6, 2018
Last Update Posted : November 6, 2018
Sponsor:
Information provided by (Responsible Party):
HaEmek Medical Center, Israel

Brief Summary:

Excessive bleeding after normal birth or cesarean section is defined as blood loss of 1000 mL or more (clinically estimated) within 24 hours after birth. It occurs in about 5% among postpartum women. Postpartum hemorrhage is a leading cause of morbidity and mortality among women giving birth. Postpartum hemorrhage may lead to hemorrhagic shock, renal failure, respiratory failure, need for surgical intervention, blood transfusion and hysterectomy.

The cornerstone of effective treatment is rapid diagnosis and intervention in time. However, in a number of cases there is an underestimation of the volume of blood loss which may lead to delay in diagnosis and treatment. The consequences are even graver in women who delivered by a cesarean section, since unlike a normal birth in which the bleeding is external and visible, the bleeding is usually intra-abdominal, and so the delay in diagnosis may be even longer.

The Inferior Vena Cava (IVC) is a flexible blood vessel sensitive to intravascular blood volume, and its diameter varies accordingly. Its diameter reflects the pressure in the right atrium, which is a measure of the cardiac preload. A number of studies have shown that the IVC diameter changes, before the variations in vital and clinical signs.

Recently, IVC diameter has been assessed as an assessment of intravenous fluid balance in hemodynamically stable patients with a risk of sub-volume shock. The authors concluded that the IVC measurement is a good noninvasive method, compared to catheter insertion into the right atrium, and it is available as a bedside procedure.

In obstetrics the use of IVC to determine blood loos was not widely examined and there is no information regarding the use of IVC diameter as a predictor or as a detection method of postpartum bleeding.

In this study the investigators aim to examine the correlation between IVC diameter and the volume of postpartum blood loss.


Condition or disease Intervention/treatment
Other Immediate Postpartum Hemorrhage, With Delivery Diagnostic Test: Ultrasound

Layout table for study information
Study Type : Observational
Estimated Enrollment : 108 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Correlation Between Inferior Vena Caval Diameter and the Volume of Postpartum Blood Loss
Estimated Study Start Date : November 10, 2018
Estimated Primary Completion Date : April 30, 2019
Estimated Study Completion Date : April 30, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bleeding

Group/Cohort Intervention/treatment
Research group
Women with early postpartum hemorrhage.
Diagnostic Test: Ultrasound
Ultrasound to measure the IVC diameter. The IVC diameter will be measured in the inspirium and the expirium, and the collapsibility index will be recorded.

Control group
Postpartum women without abnormal bleeding.
Diagnostic Test: Ultrasound
Ultrasound to measure the IVC diameter. The IVC diameter will be measured in the inspirium and the expirium, and the collapsibility index will be recorded.




Primary Outcome Measures :
  1. To examine the correlation between IVC diameter and the volume of postpartum blood loss. [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. To create a normogram of IVC diameter in postpartum women and to check whether there is a cutt-of value that appears before the onset of clinical signs of blood loss. [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   postpartum women
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Postpartum women.
Criteria

Inclusion Criteria:

  • Women over the age of 18 after birth
  • Single pregnancy
  • Vaginal birth
  • Term pregnancy (gestational age between week 37-42)
  • The newborn is appropriate for gestational age (10-90 percentile)

Exclusion Criteria:

  • Gestational or pre-pregnancy hypertension
  • Heart, liver, or chronic kidney disease
  • Women who delivered newborn with major malformation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03732079


Contacts
Layout table for location contacts
Contact: Manal Massalha, MD 0506415166 manal.massalha@clalit.org.il
Contact: Raed Salim, MD salim_ra@clalit.org.il

Sponsors and Collaborators
HaEmek Medical Center, Israel
Investigators
Layout table for investigator information
Principal Investigator: Manal Massalha, Massalha Emek Medical Center
Publications of Results:

Layout table for additonal information
Responsible Party: HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier: NCT03732079    
Other Study ID Numbers: HaEmek
First Posted: November 6, 2018    Key Record Dates
Last Update Posted: November 6, 2018
Last Verified: November 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by HaEmek Medical Center, Israel:
Inferior Vena Cava Diameter
Additional relevant MeSH terms:
Layout table for MeSH terms
Postpartum Hemorrhage
Hemorrhage
Pathologic Processes
Obstetric Labor Complications
Pregnancy Complications
Puerperal Disorders
Uterine Hemorrhage